Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage - a Prospective Randomized Open Blinded End-point Trial

Inclusion Criteria: * Age 18-80 years * NIHSS ≥8 at randomization * Stroke onset \<6h * Pre-randomization head CT demonstrating an acute, primary lobar ICH * ICH volume 30 to 80 mL * Glasgow Coma Score (GCS) 5 to 12 * Pre-stroke independence (modified Rankin Score 0 to 2) * Ability to provide informed consent * No history of prior stroke Exclusion Criteria: * Hemorrhage caused by head trauma * Medical history or neuroimaging findings suggestive of ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, Moyamoya disease, venous sinus thrombosis, mass or tumor, hemorrhagic conversion of an ischemic infarct * Bilateral fixed dilated pupils * Extensor motor posturing * Intraventricular extension of the hemorrhage is visually estimated to involve \>50% of either of the lateral ventricles * Primary Thalamic and basal ganglia ICH * Infratentorial intraparenchymal hemorrhage including midbrain, pontine, or cerebellar * Current use of low molecular weight heparins in therapeutic dose * Evidence of active bleeding * Uncorrected coagulopathy or known clotting disorder * Platelet count \< 75,000, International Normalized Ratio (INR) \> 1.4 after correction * End stage renal disease * Patients with a mechanical heart valve * End-stage liver disease * Epilepsy with grand mal seizures * History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements * Positive urine or serum pregnancy test in female subjects without documented history of surgical sterilization or post-menopausal * Known life-expectancy of less than 6 months * No reasonable expectation of recovery, Do-Not-Resuscitate (DNR), or comfort measures only prior to randomization * Participation in a concurrent interventional medical investigation or clinical trial * Inability or unwillingness of subject or legal guardian/representative to give written informed consent * Any condition that would represent a contraindication for cerebrolysin administration